A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Ondansetron (Zofran) IV: Drug Safety Communication – QT prolongation. According to the Food & Drug Administration FDA’s MedWatch:
32 mg single intravenous dose may affect the electrical activity of the heart, which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes.
For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Ondansetron (Zofran) IV: Drug Safety Communication – QT prolongation.
To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.
If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.